ArticleDer Urologe. Ausg. A2010
[Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study].
Article in Der Urologe. Ausg. A, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults.Deutsches Arzteblatt international · 2017Guideline
- [National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients].Der Urologe. Ausg. A · 2011Pooled it
- Recurrent Cystitis in Women-A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy.Antibiotics (Basel, Switzerland) · 2024Article
- Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study.Scientific reports · 2023Article
- Decreasing susceptibility of bacteria to ampicillin/ sulbactam and third generation cephalosporins in urinary tract infections.Current urology · 2022Article
- Metabolomics Study on Pathogenic and Non-pathogenicMetabolites · 2020Article
- [Self-reported infections in the German National Cohort (GNC) in the context of the current research landscape].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Article
- [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].Der Anaesthesist · 2019Review
- Antibiotic-Resistant E. coli in Uncomplicated Community-Acquired Urinary Tract Infection.Deutsches Arzteblatt international · 2018Article
- [Urinary tract infections : What has been confirmed in therapy?]Der Internist · 2017Review
- Local epidemiology and resistance profiles in acute uncomplicated cystitis (AUC) in women: a prospective cohort study in an urban urological ambulatory setting.BMC infectious diseases · 2017Article
- [Urinary tract infections in the elderly].Der Urologe. Ausg. A · 2016Review
- Surveillance of multidrug resistant uropathogenic bacteria in hospitalized patients in Indian.Asian Pacific journal of tropical biomedicine · 2013Article
- Resistance profiles of urinary tract infections in general practice--an observational study.BMC urology · 2012Article
- Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Infection · 2012Review
- Global fluoroquinolone resistance epidemiology and implictions for clinical use.Interdisciplinary perspectives on infectious diseases · 2012Article
- Uncomplicated urinary tract infections.Deutsches Arzteblatt international · 2011Article
- [New S3 guidelines "uncomplicated urinary tract infections"].Der Urologe. Ausg. A · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUncomplicated cystitis in women is among the most frequent infections in the community setting. The German results of the international ARESC Study are reported concerning clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. PATIENTS AND
methodsPatients between 18 and 65 years of age with symptoms of uncomplicated cystitis were consecutively enrolled and investigated clinically including urinalysis and urine culture. Uropathogens were identified and their susceptibility was tested for nine antimicrobials
resultsIn Germany a total of 442 patients were enrolled and 412 were eligible. A positive urine culture (cfu>/=10(4)/ml) was found in 335 (81.3%); 325 (97.1%) of them had a monoinfection. A total of 317 uropathogens were further analyzed in a central laboratory (Genua). Escherichia coli was the most frequent (76.7%), followed by Proteus mirabilis (4.7%), Staphylococcus saprophyticus (2.8%), Klebsiella pneumoniae (2.5%), enterococci (2.5%), and Staphylococcus aureus (2.2%). E. coli showed the highest rate of susceptibility to fosfomycin (97.9%) followed by mecillinam (97.5%), nitrofurantoin (95.4%), and ciprofloxacin (95.4%). The lowest rate was found for ampicillin (59.2%) followed by cotrimoxazole (74.0%). For the total spectrum the order was fosfomycin (96.1%), mecillinam (97.5%), ciprofloxacin (92.3%), and nitrofurantoin (86.3%). The lowest rates were found again for ampicillin (56.6%) and cotrimoxazole (73.9%).
conclusionsFosfomycin, mecillinam (not available in Germany), and nitrofurantoin have preserved their in vitro activity and are suitable for empiric therapy. Because of increasing resistance rates cotrimoxazole (trimethoprim) and fluoroquinolones are generally not recommended as first-choice drugs for empiric therapy of female patients with uncomplicated cystitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.